Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

Bio­gen slash­es Aduhelm price in half, fore­shad­ows sig­nif­i­cant lay­offs as sales con­tin­ue to stag­nate

In a sur­prise move, Bio­gen an­nounced Mon­day that it will cut the price of its con­tro­ver­sial Alzheimer’s drug Aduhelm in half, slash­ing the cost from $56,000 to $28,000.

The sud­den dis­count marks a sud­den turn­around for the big biotech as it strug­gles to turn around a drug whose stuck-in-the-mud sales and po­lit­i­cal ram­i­fi­ca­tions have sent the com­pa­ny in­to tur­moil and trig­gered the oust­ing of its long­time chief sci­en­tist. Bio­gen’s lead­er­ship had re­sist­ed calls since June to re­duce the price of the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.